Gilead Sciences, Inc. (GILD)
NASDAQ: GILD · Real-Time Price · USD
146.34
+0.66 (0.45%)
Aug 31, 2026, 4:00 PM EDT - Market closed
Gilead Sciences Revenue
Gilead Sciences had revenue of $7.80B in the quarter ending June 30, 2026, with 10.18% growth. This brings the company's revenue in the last twelve months to $30.46B, up 5.52% year-over-year. In the year 2025, Gilead Sciences had annual revenue of $29.44B with 2.40% growth.
Revenue (ttm)
$30.46B
Revenue Growth
+5.52%
P/S Ratio
5.96
Revenue / Employee
$1,791,588
Employees
17,000
Market Cap
181.46B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 29.44B | 689.00M | 2.40% |
| Dec 31, 2024 | 28.75B | 1.64B | 6.04% |
| Dec 31, 2023 | 27.12B | -165.00M | -0.60% |
| Dec 31, 2022 | 27.28B | -24.00M | -0.09% |
| Dec 31, 2021 | 27.31B | 2.62B | 10.60% |
| Dec 31, 2020 | 24.69B | 2.24B | 9.98% |
| Dec 31, 2019 | 22.45B | 322.00M | 1.46% |
| Dec 31, 2018 | 22.13B | -3.98B | -15.24% |
| Dec 31, 2017 | 26.11B | -4.28B | -14.09% |
| Dec 31, 2016 | 30.39B | -2.25B | -6.89% |
| Dec 31, 2015 | 32.64B | 7.75B | 31.13% |
| Dec 31, 2014 | 24.89B | 13.69B | 122.19% |
| Dec 31, 2013 | 11.20B | 1.50B | 15.46% |
| Dec 31, 2012 | 9.70B | 1.32B | 15.70% |
| Dec 31, 2011 | 8.39B | 435.97M | 5.48% |
| Dec 31, 2010 | 7.95B | 938.04M | 13.38% |
| Dec 31, 2009 | 7.01B | 1.68B | 31.40% |
| Dec 31, 2008 | 5.34B | 1.11B | 26.14% |
| Dec 31, 2007 | 4.23B | 1.20B | 39.78% |
| Dec 31, 2006 | 3.03B | 997.74M | 49.19% |
| Dec 31, 2005 | 2.03B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Johnson & Johnson | 97.93B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
GILD News
- 3 days ago - Gilead Sciences Stock (GILD) Slips 2% Despite FDA Approval of Bixlenvo - TipRanks
- 4 days ago - Gilead’s Bixlenvo approved by FDA for virologically suppressed adults with HIV - TheFly
- 4 days ago - US FDA approves Gilead's once-daily combination pill for HIV treatment - Reuters
- 4 days ago - FDA approves daily HIV pill from Gilead designed to simplify treatment for some patients - CNBC
- 4 days ago - U.S. FDA Approves Gilead's Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens - Business Wire
- 5 days ago - Gilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences - Business Wire
- 7 days ago - Gilead says EC grants marketing authorization for Trodelvy/Keytruda combination - TheFly
- 7 days ago - European Commission Expands Role of Gilead's Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status - Business Wire